Current best practices and rationalistic perspectives in causation-based prevention, early detection and multidisciplinary treatment of breast and gastric cancer


Gastric & Breast Cancer e-journal
DOI: 10.2122/gbc.2007.0057

COMMENTARY

 

Prevention of hereditary cancer syndromes
Dimosthenis Ziogas, M.D. and Charalampos Batsis, M.D.
 


Breast, colorectal and gastric cancers affect approximately 3 million people and kill over 1,6 million patients each year worldwide [1]. Primary prevention is obviously the most promising research strategy to save the lives of these patients. Although Effective chemoprevention drugs have been developed as tamoxifen for the prevention of women with a moderate or high risk of breast cancer [2] and aspirin or COX-2 inhibitors for the prevention of colorectal cancer [3 they are not in wide clinical use because if their adverse effects in health individuals and for various other reasons [2,3]

Find Delta Dental, MetLife Dental, Aetna Dentist, New York Dentist, San Francisco Dentist, Boston Dentist, Chicago Dentist, Los Angeles Dentist & San Diego Dentist at DoctorsImprovingHealthcare.org.

Online ISSN : 1109 - 7647
   Print ISSN : 1109 - 7655

We subscribe to the HONcode principles of the HON Foundation. Click to verify. We subscribe to the HONcode principles. Verify here.
please, read our policy about privacy and confidentiality of information and transparency of sponsorship

last update: 3 February 2004